Summary
Vertex Pharmaceuticals Inc. reported solid financial results for the second quarter and first half of 2025. Total revenues grew 12% year-over-year to $2.96 billion for the quarter, driven by strong performance in product revenues, which increased by 11% to $2.94 billion. This growth was primarily attributed to continued demand for TRIKAFTA/KAFTRIO and the early contributions from new product launches, including ALYFTREK and JOURNAVX. The company also saw significant growth in its pipeline, with key developments in its Type 1 Diabetes, IgA Nephropathy, and Sickle Cell Disease programs. The company reported a net income of $1.03 billion for the quarter, a substantial turnaround from the net loss of $3.59 billion in the prior year period, which was heavily impacted by the Alpine acquisition's R&D expenses. For the six-month period, net income was $1.68 billion, compared to a net loss of $2.49 billion in the prior year. The company's cash position remains strong, with total cash, cash equivalents, and marketable securities reaching $12.0 billion. Management expects existing liquidity to be sufficient for at least the next twelve months, supported by ongoing operations and a robust product portfolio.
Financial Highlights
46 data points| Revenue | $2.96B |
| Cost of Revenue | $407.50M |
| Gross Profit | $2.56B |
| SG&A Expenses | $424.60M |
| Operating Expenses | $1.81B |
| Operating Income | $1.15B |
| Net Income | $1.03B |
| EPS (Basic) | $4.02 |
| EPS (Diluted) | $3.99 |
| Shares Outstanding (Basic) | 256.70M |
| Shares Outstanding (Diluted) | 258.90M |
Key Highlights
- 1Total revenues for Q2 2025 increased by 12% to $2.96 billion, driven by an 11% rise in net product revenues to $2.94 billion.
- 2Net income for Q2 2025 was $1.03 billion, a significant improvement from a net loss of $3.59 billion in Q2 2024, largely due to the absence of large acquired R&D expenses.
- 3The company's strong cash position was maintained, with total cash, cash equivalents, and marketable securities reaching $12.0 billion as of June 30, 2025.
- 4ALYFTREK saw continued progress with new approvals and reimbursement agreements in Europe and Canada, alongside regulatory reviews in other regions.
- 5CASGEVY secured access for eligible patients in 10 countries, with patient infusions increasing, indicating steady commercial uptake.
- 6The launch of JOURNAVX in the US is progressing well, with broad payer access and inclusion in over 500 hospital formularies.
- 7The pipeline remains active, with completed enrollment in key Phase 3 trials for povetacicept (IgAN) and continued progress in Type 1 Diabetes (zimislecel) and APOL1-mediated kidney disease (inaxaplin).